0 Комментарии
0 Поделились
109 Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Новости
- ИССЛЕДОВАТЬ
-
Страницы
-
Группы
-
Мероприятия
-
Reels
-
Статьи пользователей
-
Offers
-
Jobs
-
Войдите, чтобы отмечать, делиться и комментировать!
-
Castleman Disease Treatment Market Regulatory Framework and Orphan Drug IncentivesThe regulatory landscape for Castleman disease treatment has evolved significantly to accommodate rare disease drug development, with specialized pathways and incentives that recognize the challenges of conducting traditional large-scale clinical trials in small patient populations. The U.S. Food and Drug Administration granted siltuximab orphan drug designation in 2007 and approved it for iMCD...0 Комментарии 0 Поделились 121 Просмотры 0 предпросмотр
-
Castleman Disease Treatment Market Regulatory Framework and Orphan Drug IncentivesThe regulatory landscape for Castleman disease treatment has evolved significantly to accommodate rare disease drug development, with specialized pathways and incentives that recognize the challenges of conducting traditional large-scale clinical trials in small patient populations. The U.S. Food and Drug Administration granted siltuximab orphan drug designation in 2007 and approved it for iMCD...0 Комментарии 0 Поделились 103 Просмотры 0 предпросмотр